{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:51Z","timestamp":1791829251087,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.trsl.2019.12.002","type":"journal-article","created":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T09:43:30Z","timestamp":1577267010000},"page":"16-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model"],"prefix":"10.1016","volume":"218","author":[{"given":"Mart","family":"Toots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Joong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Natchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Plemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2019.12.002_bib0001","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/irv.12486","article-title":"Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness","volume":"12","author":"Rolfes","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.trsl.2019.12.002_bib0002","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1016\/j.vaccine.2014.10.020","article-title":"How high is a high risk? Prioritising high-risk individuals in an influenza pandemic","volume":"32","author":"Littmann","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2019.12.002_bib0003","doi-asserted-by":"crossref","first-page":"634","DOI":"10.15585\/mmwr.mm6722a4","article-title":"Update: influenza activity in the United States during the 2017-18 season and composition of the 2018-19 influenza vaccine","volume":"67","author":"Garten","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2019.12.002_bib0004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0006","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1016\/j.vaccine.2019.08.069","article-title":"Modelling of optimal timing for influenza vaccination as a function of intraseasonal waning of immunity and vaccine coverage","volume":"37","author":"Costantino","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2019.12.002_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/375799","article-title":"High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza","volume":"188","author":"Shiraishi","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0008","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/AAC.49.2.556-559.2005","article-title":"Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations","volume":"49","author":"Abed","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trsl.2019.12.002_bib0009","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1099\/vir.2008.007260-0","article-title":"High prevalence of amantadine resistance among circulating European porcine influenza A viruses","volume":"90","author":"Krumbholz","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008965.pub4","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trsl.2019.12.002_bib0011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients","volume":"207","author":"Muthuri","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0012","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: a clinical perspective","volume":"31","author":"Lee","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0013","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.trsl.2019.12.002_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa","volume":"83","author":"Hurt","year":"2009","journal-title":"Antivir Res"},{"key":"10.1016\/j.trsl.2019.12.002_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcv.2010.02.019","article-title":"Oseltamivir-induced resistant pandemic A\/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"48","author":"Esposito","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0016","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trsl.2019.12.002_bib0017","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2019.12.002_bib0018","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.trsl.2019.12.002_bib0019","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2019.12.002_bib0020","first-page":"367","article-title":"Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir","volume":"221","author":"Chesnokov","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/infdis\/jiz418","article-title":"Impact of the baloxavir-resistant polymerase acid (PA) I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains","volume":"221","author":"Checkmahomed","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trsl.2019.12.002_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.trsl.2019.12.002_bib0024","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0025","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2019.12.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01217-18","article-title":"Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing","volume":"93","author":"Goldhill","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2019.12.002_bib0028","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/v20801530","article-title":"Animal models for influenza virus pathogenesis and transmission","volume":"2","author":"Bouvier","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2019.12.002_bib0029","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2018.1540586","article-title":"Animal models used to assess influenza antivirals","volume":"13","author":"Mifsud","year":"2018","journal-title":"Expert Opin Drug Dis"},{"key":"10.1016\/j.trsl.2019.12.002_bib0030","article-title":"Historical H1N1 influenza virus imprinting increases vaccine protection by influencing the activity and sustained production of antibodies elicited at vaccination in ferrets","volume":"7","author":"Francis","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2019.12.002_bib0031","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1128\/JVI.00898-16","article-title":"Identification and characterization of influenza virus entry inhibitors through dual myxovirus high-throughput screening","volume":"90","author":"Weisshaar","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100926","article-title":"Influenza vaccination accelerates recovery of ferrets from lymphopenia","volume":"9","author":"Music","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2019.12.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157903","article-title":"Peripheral leukocyte migration in ferrets in response to infection with seasonal influenza virus","volume":"11","author":"Music","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2019.12.002_bib0034","article-title":"Drugs for influenza treatment: is there significant news?","volume":"6","author":"Principi","year":"2019","journal-title":"Front Med-Lausanne"},{"key":"10.1016\/j.trsl.2019.12.002_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01946","article-title":"Treating influenza infection, from now and into the future","volume":"9","author":"Davidson","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0036","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/JVI.73.7.5903-5911.1999","article-title":"A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans","volume":"73","author":"Lu","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0037","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/JVI.74.3.1443-1450.2000","article-title":"Distinct pathogenesis of Hong Kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses","volume":"74","author":"Dybing","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.00080","article-title":"Using the ferret as an animal model for investigating influenza antiviral effectiveness","volume":"7","author":"Oh","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.trsl.2019.12.002_bib0039","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/IDR.S58551","article-title":"Modeling human influenza infection in the laboratory","volume":"8","author":"Radigan","year":"2015","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.trsl.2019.12.002_bib0040","doi-asserted-by":"crossref","first-page":"e58337","DOI":"10.1371\/journal.pone.0058337","article-title":"Clinical profiles associated with influenza disease in the ferret model","volume":"8","author":"Stark","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2019.12.002_bib0041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.trsl.2019.12.002_bib0042","doi-asserted-by":"crossref","first-page":"e27512","DOI":"10.1371\/journal.pone.0027512","article-title":"Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2019.12.002_bib0043","unstructured":"Roche, Announces FDA Approval of Xofluza (baloxavir marboxil) for Influenza; available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2018-10-24.htm. 2018."},{"key":"10.1016\/j.trsl.2019.12.002_bib0044","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.326.7401.1235","article-title":"Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials","volume":"326","author":"Cooper","year":"2003","journal-title":"Brit Med J"},{"key":"10.1016\/j.trsl.2019.12.002_bib0045","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.trsl.2019.12.002_bib0046","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1093\/jac\/dku146","article-title":"Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact","volume":"69","author":"Oh","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trsl.2019.12.002_bib0047","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1750-2659.2011.00235.x","article-title":"Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung","volume":"5","author":"Wong","year":"2011","journal-title":"Influenza Other Resp"},{"key":"10.1016\/j.trsl.2019.12.002_bib0048","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2011.05.008","article-title":"Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets","volume":"91","author":"Govorkova","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trsl.2019.12.002_bib0049","doi-asserted-by":"crossref","first-page":"e94090","DOI":"10.1371\/journal.pone.0094090","article-title":"Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir","volume":"9","author":"Marriott","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2019.12.002_bib0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient's perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.trsl.2019.12.002_bib0051","first-page":"189","article-title":"The challenge of patient adherence","volume":"1","author":"Martin","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.trsl.2019.12.002_bib0052","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","article-title":"The impact of medication regimen factors on adherence to chronic treatment: a review of literature","volume":"31","author":"Ingersoll","year":"2008","journal-title":"J Behav Med"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524419302567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524419302567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:39:59Z","timestamp":1761827999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524419302567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":52,"alternative-id":["S1931524419302567"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2019.12.002","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}